CD4; T-cell; lymphoma; leukemia; chimeric antigen; CAR-T
Showing 1 - 25 of >10,000
T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)
Recruiting
- T-cell Lymphoma
- T-cell Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
T Cell Lymphoblastic Lymphoma Trial in Beijing (BT-007 CD7 CAR-T cells)
Recruiting
- T Cell Lymphoblastic Lymphoma
- BT-007 CD7 CAR-T cells
-
Beijing, ChinaBeijing Cancer Hospital
Sep 22, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- CD4CAR
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023
B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,
Active, not recruiting
- B-Cell Acute Lymphoblastic Leukemia, Adult
- +2 more
- Fludarabine
- +2 more
-
Maywood, IllinoisLoyola University
Aug 11, 2022
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem
Not yet recruiting
- Hematologic Malignancy
- +5 more
- autologous hematopoietic stem cells added to planned CAR T
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
May 31, 2023
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)
Recruiting
- Acute Lymphocytic Leukemia
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous
Suspended
- B Cell Lymphoma
- +2 more
- Fludarabine
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Sep 8, 2022
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)
Active, not recruiting
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- CD19-CD22 CAR-T cells
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 2, 2022
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei
Recruiting
- Diffuse Large B Cell Lymphoma
- +4 more
- CD19-targeted chimeric antigen receptor T-cell
-
Kaohsiung, Taiwan
- +2 more
Oct 25, 2022
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
Not yet recruiting
- Lymphoma
- Chimeric Antigen Receptor
- (no location specified)
Oct 24, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)
Not yet recruiting
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- ThisCART19A
- +3 more
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 28, 2022
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023